Suppr超能文献

血管收缩耦联因子6对人血管内皮细胞基因表达谱的影响:不对称二甲基精氨酸释放增加

Effect of vasoconstrictor coupling factor 6 on gene expression profile in human vascular endothelial cells: enhanced release of asymmetric dimethylarginine.

作者信息

Tanaka Makoto, Osanai Tomohiro, Murakami Reiichi, Sasaki Satoko, Tomita Hirofumi, Maeda Naotaka, Satoh Kei, Magota Koji, Okumura Ken

机构信息

Second Department of Internal Medicine, Hirosaki University School of Medicine, Osaka, Japan.

出版信息

J Hypertens. 2006 Mar;24(3):489-97. doi: 10.1097/01.hjh.0000209985.66853.1e.

Abstract

BACKGROUND

Coupling factor 6 (CF6), a component of ATP synthase, inhibits phospholipase A2 and induces vasoconstriction. However, because arachidonic acid acts in the widespread fields of vascular biology, CF6 might exert profound effects in addition to vasoconstriction. We investigated the effect of CF6 on the gene expression profile in human umbilical vein endothelial cells.

METHODS AND RESULTS

The increased gene expression after 24-h exposure to CF6 at 10 mol/l, assessed by cDNA microarray (n = 3), included neuregulin-1 (1.84 +/- 0.07 fold compared with control, P < 0.05) and relaxin-1 (1.74 +/- 0.20, P < 0.05), both relating to congestive heart failure, urokinase type plasminogen activator receptor (1.77 +/- 0.24, P = 0.06) and estrogen receptor beta (1.74 +/- 0.36, P = 0.08), both relating to vascular inflammation and cell infiltration, and protein arginine methyltransferase (PRMT-1; 1.73 +/- 0.20, P < 0.05). Out of these genes, the enzyme relating to the synthesis (PRMT-1) of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS), was further examined concomitantly with the degradation enzyme, dimethylarginine dimethylaminohydrolase 2 (DDAH-2). The ratio of PRMT-1 to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA, measured by real-time quantitative reverse transcription-polymerase chain reaction, was increased by 9 +/- 2% (n = 10, P < 0.01) at 48 h after CF6 at 10 mol/l, whereas the ratio of DDAH-2 to GAPDH was decreased by 12 +/- 2% (n = 8, P < 0.01). DDAH-2 protein and activity were decreased by 28 +/- 5% (n = 5, P < 0.01) and 19 +/- 2% (n = 6, P < 0.01) by CF6, respectively. ADMA release was enhanced by 20 +/- 8% and NOS activity was decreased by 13 +/- 1% (both n = 8, P < 0.05) by CF6.

CONCLUSIONS

CF6 changes the gene expression profile to be proatherogenic and functions as a novel stimulator for ADMA release by enhancing its synthesis and suppressing its degradation.

摘要

背景

耦合因子6(CF6)是ATP合酶的一个组成部分,可抑制磷脂酶A2并诱导血管收缩。然而,由于花生四烯酸在血管生物学的广泛领域发挥作用,CF6可能除了血管收缩外还会产生深远影响。我们研究了CF6对人脐静脉内皮细胞基因表达谱的影响。

方法与结果

通过cDNA微阵列(n = 3)评估,在10 μmol/l的CF6作用24小时后基因表达增加,其中包括与充血性心力衰竭相关的神经调节蛋白-1(与对照组相比为1.84 ± 0.07倍,P < 0.05)和松弛素-1(1.74 ± 0.20,P < 0.05),与血管炎症和细胞浸润相关的尿激酶型纤溶酶原激活物受体(1.77 ± 0.24,P = 0.06)和雌激素受体β(1.74 ± 0.36,P = 0.08),以及蛋白质精氨酸甲基转移酶(PRMT-1;1.73 ± 0.20,P < 0.05)。在这些基因中,与一氧化氮合酶(NOS)的内源性抑制剂不对称二甲基精氨酸(ADMA)合成相关的酶(PRMT-1)与降解酶二甲基精氨酸二甲胺水解酶2(DDAH-2)同时进行了进一步研究。通过实时定量逆转录-聚合酶链反应测量,在10 μmol/l的CF6作用48小时后,PRMT-1与甘油醛-3-磷酸脱氢酶(GAPDH)mRNA的比值增加了9 ± 2%(n = 10,P < 0.01),而DDAH-2与GAPDH的比值降低了12 ± 2%(n = 8,P < 0.01)。CF6使DDAH-2蛋白和活性分别降低了28 ± 5%(n = 5,P < 0.01)和19 ± 2%(n = 6,P < 0.01)。CF6使ADMA释放增加了20 ± 8%,NOS活性降低了13 ± 1%(两者n = 8,P < 0.05)。

结论

CF6改变基因表达谱,使其具有促动脉粥样硬化性,并通过增强ADMA的合成和抑制其降解,作为ADMA释放的新型刺激物发挥作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验